A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Purpose

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Condition

  • Diabetes Mellitus, Type 2

Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Have type 2 diabetes - Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening - Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive - Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Exclusion Criteria

  • Have type 1 diabetes

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
LY3938577 		Participants will receive LY3938577 subcutaneously (SC)
  • Drug: LY3938577
    Administered SC
Active Comparator
Degludec 		Participants will receive degludec SC
  • Drug: Degludec
    Administered SC

Recruiting Locations

Accellacare - Wilmington
Wilmington, North Carolina 28401
Contact:
910-799-5500

Holston Medical Group
Bristol, Tennessee 37620
Contact:
423-990-2478

Chrysalis Clinical Research
St. George, Utah 84790
Contact:
435-656-1704

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
317-615-4559
LillyTrials@Lilly.com